In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Xoma, with a price target of $97.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Xoma’s strategic acquisitions and partnerships. The recent acquisition of Generation Bio is seen as a significant opportunity for Xoma to expand its royalty and milestone revenue streams, particularly through Generation Bio’s collaboration with Moderna. This collaboration includes potential high-value milestones and tiered royalties, which could provide substantial future cash flows for Xoma.
Furthermore, Pantginis appreciates Xoma’s ability to creatively manage its portfolio of partnered assets, which includes both approved and late-stage assets already generating revenue. The acquisition of Generation Bio, despite its financial challenges, is viewed as a strategic move to leverage its ctLNP delivery platform and capitalize on its partnerships. This strategic approach, coupled with Xoma’s non-dilutive cash generation capabilities, underpins Pantginis’s positive outlook and Buy rating for the stock.
According to TipRanks, Pantginis is a 5-star analyst with an average return of 10.7% and a 47.81% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Kura Oncology, Celldex, and Esperion.
In another report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $45.00 price target.